Insmed reported $-95317000 in EBIT for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebit Change
Acelrx Pharmaceuticals ACRX:US $ -8633000 1.05M
Alexion Pharmaceuticals ALXN:US $ 816.7M 185.9M
Arena Pharmaceuticals ARNA:US $ -124485000 19.91M
Biomarin Pharmaceutical BMRN:US $ -35997000 47.67M
Cytokinetics CYTK:US $ -69201000 14.4M
Flexion Therapeutics FLXN:US $ -24158000 7.28M
Gilead Sciences GILD:US $ 3883M 1637M
Insmed INSM:US $ -95317000 6.75M
Mirati Therapeutics MRTX:US $ -79499000 84.69M
Novartis NVS:US 3.48B 77M
Regeneron Pharmaceuticals REGN:US $ 1847.2M 1500M
Sarepta Therapeutics SRPT:US $ -34458000 133.12M
Seattle Genetics SGEN:US $ -297963000 208.36M
Ultragenyx Pharmaceutical RARE:US $ -89828000 7.05M
Vertex Pharmaceuticals VRTX:US $ 1055.71M 1092.07M